16 Jan 2026 Foodtech at a crossroads: recalibration, regulation, and reality

What 2026 may hold for innovators, investors, and operators across the food system….

The foodtech sector is entering 2026 with a mix of hard lessons, strategic resets, and cautious optimism. After years of hype cycles, inflated valuations, and bold promises to “fix the food system,” the industry is now confronting a more sober reality.

As one founder put it, it feels less like winter is ending and more like an ice age is beginning.

Across categories — from alternative proteins to AI‑driven manufacturing — the question is no longer “How big can this get?” but “What problem are you solving, and who will pay for it?”

Investors are demanding clearer business cases, regulators are tightening scrutiny, and startups are being forced to sharpen their value propositions.

Here is a food‑industry‑focused breakdown of the nine major themes shaping the year ahead.

Alt‑protein recalibration

The alternative protein sector is undergoing a deep reset. Many companies still struggle to articulate a clear customer pain point or a viable path to profitability. Some have shut down, others have pivoted to higher‑value niches, and many are consolidating.

While demand for protein — especially functional proteins for beverages and high‑protein foods — remains strong, the economics of precision fermentation and plant‑based meat remain challenging.

Several players are shifting toward premium dairy proteins like lactoferrin or functionalised whey, where margins are more promising.

Egg‑replacement technologies are gaining traction, with companies like EVERY moving from pilot scale to selling metric tons of product to major food manufacturers. But the sector is also seeing IP disputes and competitive tension.

The future of self‑GRAS

Proposed reforms to the US self‑GRAS process have sparked concern across foodtech. Eliminating self‑affirmation could create massive regulatory bottlenecks at an already stretched FDA.

Critics argue that reform is needed, but a full overhaul could stall innovation and overwhelm the system.

The FDA’s draft rule is currently under White House review, and legal challenges are possible if the agency attempts to mandate submissions without legislative changes.

Nutrition in the age of GLP‑1

GLP‑1 drugs like Ozempic are reshaping consumer behaviour and could dramatically alter food demand.

A key question for 2026: will GLP‑1s reduce demand for ultra‑processed foods and boost fresh produce, or will they simply inspire a new wave of highly engineered “GLP‑1‑friendly” products?

In the short term, food manufacturers and retailers are still trying to navigate this space, with some developing companion products and digital tools for users and others attempting to find natural alternatives to Ozempic et al, although the jury is still out on their efficacy.

How this fits into the ultra-processed foods debate will be interesting to monitor. Could it fundamentally reshape the American diet by slashing demand for junk food and driving sales of fresh produce?

Or is it just an opportunity for “Big Food” to design ever-more processed “solutions” to solve the problems it arguably helped to create?

Ultra‑processed foods under the microscope

Regulators are wrestling with how to define “ultra‑processed foods,” with public comments revealing just how complex the task is. Definitions range from broad (“industrial formulations”) to highly specific lists of additives.

The NOVA system remains influential but controversial, criticised for lumping nutrient‑fortified whole‑grain foods together with candy and soda.

Brands like Amy’s Kitchen and Califia Farms are exploring third‑party “non‑UPF” verification as consumer scrutiny intensifies.

MAHA, GRAS reform, and dietary guidelines

The MAHA movement’s push for cleaner labels and healthier food environments has been met with both praise and skepticism. Critics point out contradictions between stated goals and policy decisions, including cuts to hospital and nutrition‑assistance funding.

There is also concern that upcoming US Dietary Guidelines could be influenced by political agendas rather than established science.

Digitization and AI

AI is rapidly becoming embedded across the food value chain — from R&D to manufacturing, supply chain optimisation, and restaurant operations. Investors are particularly interested in tools that address labour shortages, streamline ordering and improve predictive maintenance.

Startups to watch include platforms for CPG operating systems, foodservice trade‑spend management, and AI‑enhanced quality monitoring in processing facilities.

Rubisco’s moment?

RuBisCO — one of the most abundant proteins on Earth — may finally be ready for commercial scale.

Companies in the US and New Zealand claim they’ve cracked the code on economically viable extraction from duckweed and alfalfa.

If successful, RuBisCO could become a high‑functionality plant protein rivaling egg and whey.

Crunch time for cultivated meat

Cultivated meat continues to face steep economic and political challenges. Funding has tightened, large‑scale facilities have been paused, and several companies have shut down.

Yet technical progress continues, and some players are achieving positive margins at mid‑scale production.

Regulatory approvals in Australia and New Zealand, plus new funding rounds in Europe, suggest the sector isn’t dead — just recalibrating.

Insect agriculture at a turning point

The insect‑protein sector saw major collapses in 2025: Danish insect ag co ENORM was declared bankrupt, South African BSFL startup Inseco ceased operations, and French mealworm farmer Ÿnsect went into judicial liquidation.

Yet new funding rounds in Tunisia and Finland show that investor appetite hasn’t disappeared.

Companies scaling BSFL and mealworm production insist that demand remains strong, especially for pet food and specialty ingredients.

And finally… the EPG showdown

A legal battle is unfolding over access to EPG, a low‑calorie fat replacer acquired by David Protein. Several startups allege the company is creating a monopoly by cutting off supply, while David Protein argues it has no obligation to sell to firms without long‑term contracts.

The outcome could have ripple effects across the fat‑replacer and functional‑ingredient markets.

AgFunderNews: Read the full article here